Özcan GÜR, Okay Güven KARACA, Çetin Hakan KARADAĞ, Suat CANBAZ, Mehmet KALENDER, Ata Niyazi ECEVİT, Turan EGE

In vitro effects of amiodarone on coronary artery bypass grafts

Amaç: Bu çalışmada amiodaronun en çok kullanılangreftler olan internal torasik arter (İTA), safen ven (SV)ve radial arter (RA) üzerine etkisi organ banyosundaincelendi.Çalışmaplanı: Mayıs 2008 - Ekim 2008 tarihleriarasında izole koroner arter baypas greft (KABG)ameliyatı olan 20 hasta (16 erkek, 4 kadın; ort. yaş58.4±9.9 yıl; dağılım 38-80 yıl) çalışmaya dahil edildi.İnternal torasik arter, safen ven ve radial arterler top-landı. Örnekler +4 ºC Krebs solüsyonunda laboratuvarataşındı. Örnekler Krebs solüsyonu içeren 10 ml organbanyosunda askıya alındı.Bul gu lar: Amiodaron 10-9 -10-3,5 M konsantrasyon aralı-ğında tüm greftlerde (ITA, RA, SV) doz bağımlı gevşeme-ye yol açtı (p

Amiodaronun koroner arter baypas greftleri üzerine in vitro etkileri

Background: This study aims to investigate the effects ofamiodarone on the most commonly used grafts, internalthoracic artery (ITA), saphenous vein (SV), and radialartery (RA) in organ bath. Methods: Twenty patients (16 males, 4 females; meanages 58.4±9.9 years; range 38 to 80 years) who underwentisolated coronary artery bypass graft (CABG) surgerybetween May 2008 and October 2008 were included inthis study. Internal thoracic artery, saphenous vein, andradial artery grafts were harvested. Specimens were takento laboratory in +4 ºC Krebs solution. Specimens weresuspended in 10 ml organ bath containing Krebs solution. Results: Amiodarone caused relaxation in all grafts (ITA,RA, SV) between 10-9-10-3,5 M concentration in a dosedependent manner (p

PDF

___

1. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985;89:248-58.
2. Rosenfeldt FL, He GW, Buxton BF, Angus JA. Pharmacology of coronary artery bypass grafts. Ann Thorac Surg 1999;67:878-88.
3. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983;106:788-97.
4. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol 1984;3:1059-71.
5. Mason JW. Amiodarone. N Engl J Med 1987;316:455-66.
6. Nattel S, Talajic M, Fermini B, Roy D. Amiodarone: pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-80.
7. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989;35:1882-7.
8. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-80.
9. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor- alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997;96:1386-9.
10. Perkerson KA, Gillespie EL, White CM, Kluger J, Takata H, Kardas M, et al. Impact of prophylactic amiodarone on length of hospital stay, stroke, and atrial fibrillation after cardiothoracic surgery. Pharmacotherapy 2005;25:320-4.
11. Ege T, Karaca OG, Gur O, Karadag H, Gurkan S, Duran E. The evaluation of in vitro effects of dipyridamole on coronary artery bypass grafts. Balkan Med J 2011;28:261-3.
12. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102:I112-28.
13. Ommen SR, Odell JA, Stanton MS. Atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997;336:1429-34.
14. Maisel WH, Rawn JD, Stevenson WG. Atrial fibrillation after cardiac surgery. Ann Intern Med 2001;135:1061-73.
15. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Forceon practice guidelines. Circulation 2011;123:e269-367.
16. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741-8.
17. He GW. Arterial grafts for coronary artery bypass grafting: biological characteristics, functional classification, and clinical choice. Ann Thorac Surg 1999;67:277-84.
18. He GW, Yang CQ, Graier WF, Yang JA. Hyperkalemia alters EDHF-mediated hyperpolarization and relaxation in coronary arteries. Am J Physiol 1996;271:H760-7.
19. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, et al. Difference between endothelium- dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988;319:462-7.
20. Sellke FW, Boyle EM Jr, Verrier ED. Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction. Ann Thorac Surg 1996;62:1222-8.
21. Rodrigues AJ, Evora PR, Maruo A, Schaff HV. Amiodarone causes endothelium-dependent vasodilation in canine coronary arteries. Arq Bras Cardiol 2005;84:251-5.
22. Gessner G, Heller R, Hoshi T, Heinemann SH. The amiodarone derivative 2-methyl-3-(3,5-diiodo-4-carboxymethoxybenzyl) benzofuran (KB130015) opens large-conductance Ca2+- activated K+ channels and relaxes vascular smooth muscle. Eur J Pharmacol 2007;555:185-93.
23. Traupe T, Keller M, Fojtu E, Bhattacharya I, Lang M, Ha HR, et al. Antioxidant activity and sex differences of acute vascular effects of amiodarone in advanced atherosclerosis. J Cardiovasc Pharmacol 2007;50:578-84.